CARBOGEN AMCIS was acquired by Dishman in August 2006. CARBOGEN AMCIS is a leading service provider, offering a portfolio of drug development and commercialisation services to the pharmaceutical and biopharmaceutical industries at all stages of drug development. The integrated services of CARBOGEN AMCIS provide innovative chemistry solutions to support timely and safe drug development with improved cost efficiency.

CARBOGEN AMCIS’ focus is on supporting the development process from bench to market. The breadth of capabilities span contract chemical process research and development to the supply of Active Pharmaceutical Ingredients (APIs) for preclinical studies, clinical trials and commercial use. CARBOGEN AMCIS site in Riom, France is fully dedicated to the formulation and manufacture of fill-fished drug products for parenteral applications.

Carbogen Amcis


5 November 2018
Dishman Carbogen Amcis Ltd. Announces a Successful FDA Inspection of its Site in Bavla, India

1 August 2018
Dishman Carbogen Amcis Opens Office in Kyoto, Japan

11 August 2016
Dishman Celebrates a Decade of Success Since Acquisition of CARBOGEN AMCIS